Current status and future perspectives for the treatment of resectable locally advanced esophagogastric junction cancer: A narrative review

Table 5 Clinical trials of neoadjuvant immunotherapy/targeted therapy for esophagogastric junction cancer included in this review

Study name	Neo-PLANET[13]	NEONIPIGA[14]	NRG Oncology/RTOG 1010[44]
Ref.	Tang et al[13]	Andre et al[14]	Safran et al[44]
Yr	2022	2023	2022
Study design	Phase II	Phase II	Phase III
Eligible patients	cT3-4N+, M0	cT2-4, M0, dMMR/MSI-H	cT1N1-2 or cT2-3N0-2 HER2 positive
	Gastric or EGJ cancer	Gastric or EGJ cancer	Esophageal adenocarcinoma
Experimental arm	Camrelizumab plus chemoradiotherapy	Nivolumab plus ipilimumab	Trastuzumab plus chemoradiotherapy
Control arm	NA	NA	Chemoradiotherapy
Total number of patients	36	29	203
EGJ cancer patients	53.80%	50.00%	NA
Primary endpoint	pCR	pCR	Disease-free survival
OS	NA	NA	38.5 vs 38.9 mo
pCR rate	33.30%	58.60%	27% vs 29%
R0 resection rate	91.70%	100%	98% vs 100%
Special notes	Two-year OS, 76.2%		Disease-free survival, 19.6 vs 14.2 mo

EGJ: Esophagogastric junction; pCR: Pathological complete response; NA: Not available; OS: Overall survival.